### Lecture 14: Acute Kidney Injury (AKI) Part 2

**1. Classify the causes of acute kidney injury (pre-renal, intrinsic, post-renal).**

AKI is categorized by the site of the problem:
- **Pre-renal:** Any condition that reduces **renal perfusion** (e.g., hypovolemia, heart failure, hemodynamic instability). If uncorrected, it can progress to ischemic **acute tubular necrosis (ATN)**.
- **Intrinsic renal:** Diseases of the **glomeruli, tubules, interstitium, or vessels**.
  - Glomerular: **Nephritic** or **nephrotic** syndromes.
  - Tubular: **ATN due to ischemia** or **nephrotoxins**.
  - Interstitial: **Acute interstitial nephritis (AIN)**, **acute pyelonephritis**.
  - Vascular: **Renal artery stenosis**, vasculitides, atheroembolic disease, thrombotic microangiopathies.
- **Post-renal:** **Obstruction** of urine flow anywhere from the tubules to the **urethral meatus**; may be unilateral or bilateral, partial or complete.

**2. Understand the causes and pathogenesis of toxic acute tubular necrosis (ATN).**

Toxic ATN results from tubular injury due to exogenous or endogenous toxins:
- **Contrast-induced AKI:** Iodinated contrast causes ATN via **renal vasoconstriction**, **medullary hypoxia**, and direct **cytotoxicity** (mediators include altered nitric oxide, endothelin, adenosine).
  - **Risk factors:** Underlying **CKD** (strongest), **diabetic nephropathy**, heart failure/hemodynamic instability, high contrast volume.
  - **Timeline:** Rise in creatinine typically **within 24–48 hours** post-exposure.
  - **Course/Prognosis:** Often **mild**, frequently **non-oliguric**, usually **reversible**; dialysis rarely needed.
  - **Prevention/Treatment:** **Limit contrast** and give **isotonic IV fluids** pre/post exposure; avoid contrast if possible.
- **Pigment nephropathy:**
  - **Rhabdomyolysis:** Muscle breakdown releases **myoglobin**, causing **vasoconstriction**, **oxidant tubular injury**, and **intratubular obstruction**; volume contraction worsens distal precipitation.
  - **Hemolysis:** **Free hemoglobin** is filtered, causing **hemoglobinuria**, casts, and ATN (e.g., incompatible transfusion, malaria, certain toxins).
- **Drugs:** Notably **aminoglycosides** and **amphotericin**; mechanisms vary but are grouped as **nephrotoxic ATN**.

**3. Describe the causes, diagnosis and treatment of post-renal AKI.**

- **Causes/Classification:**
  - By **duration:** Acute (hours–days), subacute (days–weeks), chronic (months–years).
  - By **location:** Anywhere along the urinary tract (tubules to urethra); one or both collecting systems may be involved.
  - By **degree:** **Partial** or **complete** obstruction.
  - Sudden, **complete bilateral** obstruction (or obstruction of a **solitary kidney**) causes acute AKI; chronic partial obstruction leads to **atrophy**, **fibrosis**, and **CKD**.
- **Diagnosis:**
  - **Imaging:** **Renal ultrasound** (look for **hydronephrosis**); **CT** as needed.
  - **Bladder catheterization:** Both diagnostic and therapeutic for lower tract obstruction.
  - **POCUS** is increasingly useful at bedside.
- **Treatment:**
  - **Urgent decompression** when indicated (e.g., **Foley catheter**, **nephrostomy tubes**, **ureteral stenting**).
  - **Treat underlying cause** (e.g., stones, tumors, strictures, prostate disease).
- **Recovery/Pathology:**
  - Recovery inversely related to duration: ~**full** if ≤7 days, ~**30%** at 28 days, **minimal** after 56 days.
  - Prolonged obstruction causes **ischemic parenchymal damage**, **glomerulosclerosis**, **tubular atrophy**, **interstitial inflammation/fibrosis**.

**4. Explain the clinical syndrome of interstitial nephritis.**

- **Acute interstitial nephritis (AIN):** An **immunologic hypersensitivity** reaction to an **antigen** (most often a **drug**, sometimes infection).
  - **Timing:** **Days to weeks** after starting the culprit agent.
  - **Common drugs (“Big 3”):** **NSAIDs**, **proton pump inhibitors**, **antibiotics**; others include **diuretics** and **immune checkpoint inhibitors**.
  - **Clinical features:**
    - Renal: **AKI** with **pyuria** (urine **white blood cells**).
    - Extra-renal (less common): **Low-grade fever**, **maculopapular rash**, **arthralgias**, **eosinophilia**.
  - **Pathogenesis:** Both **cell-mediated** (T cells, macrophages) and **antibody-mediated** mechanisms with **complement activation**, cytokine release, and **interstitial inflammatory infiltrates**. Can progress to **interstitial fibrosis** and **CKD**.
  - **Histology:** **Inflammatory infiltrates** in the interstitium.
  - **Prognosis/Treatment:** Often **reversible** if recognized early; **stop the offending drug**, consider **steroids**.
- Related interstitial entity:
  - **Pyelonephritis:** Acute ascending UTI with **neutrophilic** interstitial inflammation; presents with **fever**, **flank pain**, **N/V**; risk factors include **diabetes**, **catheters**, **vesicoureteral reflux (VUR)**, **pregnancy**; treat with **antibiotics**. Chronic/recurrent infections cause **corticomedullary scarring**; VUR/obstruction (e.g., **posterior urethral valves**) predispose.

**5. Develop an approach to the diagnosis of AKI.**

- **History:** Volume changes, **medications** (including recent additions like NSAIDs, PPIs, antibiotics, diuretics, contrast), **toxins**, comorbidities, symptoms.
- **Exam:** **Vitals**, volume/cardiovascular status, **bladder distention**, **rashes**.
- **Diagnostics:**
  - **Urinalysis with microscopy:** 
    - **Pre-renal:** Bland sediment, possible **hyaline casts**.
    - **ATN:** **Granular (“muddy brown”) casts**, **renal tubular epithelial cells/casts**.
  - **Urine electrolytes:**
    - **UNa:** Low in pre-renal (<10–20 mEq/L), higher in ATN (>20).
    - **FENa:** **<1%** suggests pre-renal; **>1%** suggests ATN. Important caveats: **diuretics**, **CKD**, **contrast use**, and **nonoliguric AKI** can limit accuracy.
    - **FEUrea:** **<35%** supports pre-renal state when diuretics confound FENa.
  - **Imaging:** Ultrasound to exclude **obstruction**.
  - **Kidney biopsy:** When concern for **GN**, **AIN**, **vasculitis**, or when diagnosis is **unclear** with unexplained hematuria/proteinuria.
- Integrate findings to distinguish **pre-renal vs intrinsic vs post-renal** and guide therapy.

**6. Differentiate the two types of renal artery stenosis (RAS).**

- **Atherosclerotic RAS (ARAS):**
  - **Prevalence:** ~**90%** of RAS.
  - **Demographics:** **>50 years**, often with other **atherosclerotic disease**.
  - **Clues:** **Resistant/accelerated hypertension**, **abdominal/flank bruits**, **PVD**, **severe retinopathy**, possible **AKI after ACEi/ARB**, **unilateral small kidney**, **hypokalemia** (RAAS activation).
  - **Imaging:** **MRA** or **CT angiography**; renal ultrasound with **Dopplers**.
- **Fibromuscular dysplasia (FMD):**
  - **Prevalence:** ~**10%** of RAS.
  - **Demographics:** **Younger women**; may involve other medium vessels (e.g., **carotid**).
  - **Clues:** **Abrupt-onset hypertension** before 50, **carotid bruit**, **abdominal bruit**.
  - **Imaging:** **CT angiography** showing **“string of beads”** (focal stenoses and dilations). Because FMD often affects **mid–distal renal artery**, **MRA is less reliable**.
- **Shared pathophysiology:** **Decreased renal perfusion** → **RAAS activation** → **angiotensin II–mediated hypertension**; can present with **AKI**, **HTN**, or **CKD** progression.

**7. Know the key treatments for specific AKI and management of the complications of AKI.**

- **Improve renal perfusion:** 
  - **Volume resuscitation** with isotonic fluids (if hypovolemic).
  - **Inotropes** for cardiac dysfunction.
  - **Vasopressors** for persistent hypotension (e.g., septic shock).
  - Temporarily **stop NSAIDs** and **RAAS inhibitors** in hemodynamically mediated AKI.
- **Treat the underlying cause:**
  - **Post-renal:** Urgent **decompression** (Foley catheter, **nephrostomy**, **ureteral stent**) and address the cause.
  - **AIN/GN/vasculitis:** **Steroids**, **immunosuppression**, **plasmapheresis** when indicated.
  - **ATN:** No proven specific therapy; management is **supportive**.
- **Supportive care for all AKI:**
  - **Avoid nephrotoxins**, **renally dose** medications.
  - Optimize **nutrition**; promptly **treat infections**.
  - Monitor and correct **electrolyte** and **acid-base** derangements.
- **Dialysis (RRT) for complications—AEIOU:**
  - **A**cidosis (refractory).
  - **E**lectrolyte abnormalities (e.g., refractory **hyperkalemia**).
  - **I**ngestions (dialyzable toxins, e.g., ethylene glycol).
  - **O**verload of volume (diuretic-resistant).
  - **U**remia (e.g., pericarditis, encephalopathy).
- **Prognosis:** AKI is often reversible but can lead to **partial recovery**, **ESRD**, or **accelerated CKD progression** (especially when superimposed on CKD).